The neurosteroid allopregnanolone as a new target for treatment of itch in atopic dermatitis
| Project/Area Number |
25870894
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pharmacology in pharmacy
Pain science
|
|---|
| Research Institution | Kyoto Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 痒み / 脳ニューロステロイド / アトピー性皮膚炎 |
|---|
| Outline of Final Research Achievements |
This study aimed to clarify the relation between the neurosteroid allopregnanolone (ALLO) and itch in atopic dermatitis (AD), and to provide a new therapeutic target for AD itch. ALLO administration significantly increased scratching behavior in AD model mice, but not in normal ones. Pharmacological analysis showed that GABAA receptor activation in the brain contributes to ALLO-induced scratching in AD mice. It has been reported that ethanol increases ALLO in the brain. Pretreatment with a synthetic inhibitor of ALLO, finasteride, suppressed ethanol-induced scratching in AD mice. Therefore, our findings indicate that endogenously produced ALLO may be involved in itch under AD conditions.
|
Report
(4 results)
Research Products
(22 results)
